Fact-checking the "AI cured cancer" hype: inside Merck/Moderna's Phase 3 mRNA vaccine win
APPSO · wechat · 2026-08-20
Viral claims of "AI cured cancer" are heavily exaggerated. The actual news: Merck and Moderna announced their personalized mRNA cancer therapy mRNA-4157 plus Keytruda met Phase 3 endpoints, significantly extending recurrence-free and distant metastasis-free survival in high-risk melanoma patients; Moderna stock surged a record 177%.
The AI role: algorithms process tumor sequencing data to predict up to 34 neoantigens most likely to trigger immune response, and Moderna's Maestro platform uses AI scheduling to keep individualized doses on time. Phase 2 already showed 44% lower recurrence risk and 65% lower distant metastasis risk versus Keytruda alone. The article also covers limits: melanoma's high mutation burden makes it an ideal target, expansion to lung, bladder and kidney cancers is still in trials, and personalization means high costs. BioNTech is developing a nearly identical therapy.
It rounds up other AI-for-science progress — AlphaFold3, Google's AI co-scientist (leukemia drug repurposing candidates in 4 hours), FutureHouse's Robin (identified a candidate for dry AMD for $10.76), Stanford's virtual lab designing 92 nanobodies — while noting most results remain preclinical.
More from AGI Musings
- "An LLM doesn't understand anything" gets the perfect parody reversal: neither do you — VoidStateKate · 2026-10-16
- Nina Schick: Europe's Policy Circle Still Doesn't Believe FSD, Orbital Compute Are Real — NinaDSchick · 2026-10-16
- Meta's Superintelligence Lab Runs 200+ Direct Reports—A Lesson for Flat Multi-Agent Systems — peterjliu · 2026-10-16
- Andy Masley lays out his version of effective altruism, pluralism over utilitarian math — RobbWiller · 2026-10-16
- We're forgetting how much of a miracle GPT-3.5-level intelligence was, and it may cost us — EigenGender · 2026-10-16
- Ex-Anthropic's McDonagh Builds Compute Intelligence Agency to Study Frontier AI Costs — McDonaghMatthew · 2026-10-16